Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1437-160X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients ; volume:37 ; number:9 ; day:26 ; month:7 ; year:2017 ; pages:1435-1440 ; date:9.2017
Rheumatology international ; 37, Heft 9 (26.7.2017), 1435-1440, 9.2017
- Urheber
-
Janssen, Carly A.
- Beteiligte Personen und Organisationen
-
Jansen, Tim L. Th. A.
Oude Voshaar, Martijn A. H.
Vonkeman, Harald E.
van de Laar, Mart A. F. J.
SpringerLink (Online service)
- DOI
-
10.1007/s00296-017-3777-3
- URN
-
urn:nbn:de:1111-201711052711
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Janssen, Carly A.
- Jansen, Tim L. Th. A.
- Oude Voshaar, Martijn A. H.
- Vonkeman, Harald E.
- van de Laar, Mart A. F. J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Adherence with urate-lowering therapies for the treatment of gout
Variation in serum urate levels in the absence of gout and urate lowering therapy
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients
Adherence with urate-lowering therapies for the treatment of gout
Variation in serum urate levels in the absence of gout and urate lowering therapy
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients
Adherence with urate-lowering therapies for the treatment of gout
Variation in serum urate levels in the absence of gout and urate lowering therapy
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study